May 10th 2024
Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.
February 3rd 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Better Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC Compared to Sunitinib
February 19th 2022A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.
Read More
Upfront Avelumab Maintenance Demonstrates Continued OS Benefit in Advanced UC
February 18th 2022An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.
Read More
PFS Prolonged With Continuous Enzalutamide After AR Inhibitor Progression in mCRPC
February 18th 2022According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Read More